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Abstract:
Small interfering RNA (siRNA) offers a great potential for the treatment of various diseases and disorders. Nevertheless, inefficient in vivo siRNA delivery hampers its translation into the clinic. While numerous successful in vitro siRNA delivery stories exist in reduced protein conditions, most studies so far overlook the influence of the biological fluids present in the in vivo environment. In this study, we compared transfection efficiency of liposomal formulations 
Introduction:
Since the discovery of small interfering RNA (siRNA) [1] [2] , a lot of effort has been put in translating it into the clinic for the treatment of different diseases 3 . In vitro there are numerous options to successfully deliver siRNA to cells under 'reduced serum conditions'. In more complex 'protein-rich' biological fluids, however, the effect of the protein corona (being formed at the surface of the nanoparticles) on the aggregation, release, uptake, intracellular trafficking and transfection of nanoparticles should not be underestimated [4] [5] [6] . Unfortunately, upon screening tens of papers which aim to optimize siRNA carriers for future in vivo use, the nanoparticles are only evaluated in unrealistic protein-free conditions, in spite of the fact that human biological fluids like e.g. blood, serum, plasma, ascites fluids, sputa, synovial fluids, ... are easily accessible. As these undiluted biological fluids contain high concentration of proteins, they more closely resemble the in vivo situation.
In vivo siRNA delivery is a complex process that includes both extracellular and intracellular barriers. Generally speaking, nanoparticles are expected to keep the cargo (i.e. siRNA) in an intact form while circulating in the biological fluids of the body. Also, pre-mature release of the siRNA from the nanoparticles and aggregation of siRNA nanoparticles in biological fluids are referred to as extracellular barriers for siRNA delivery 7 . While it is possible to determine the overall biological activity (i.e. gene knock down) of siRNA formulations in vivo, it is impossible to monitor siRNA release, aggregation and interaction of the formulations with biological membranes directly in vivo. Therefore, in vitro optimization of nanoparticlebased siRNA delivery is still needed, though should be done under conditions which are as similar as possible to the in vivo situation in which the nanoparticles are intended to be used.
A better understanding of our failure to efficiently deliver siRNA in vivo 8 should arise from a stronger knowledge on the physico-chemical and biophysical properties of siRNA delivery systems in the biofluids which are expected to be encountered. For patients diagnosed with peritoneal carcinomatosis, for example, the delivery of nanoparticles in the peritoneal cavity is being considered as a promising future therapy. Locoregional anticancer therapy allows to target the peritoneal carcinomatosis while at the same time limiting systemic toxicity.
After locoregional administration, nanoparticles come into contact with the peritoneal fluid present in the peritoneal cavity of these patients. Hence, understanding the influence of peritoneal fluid on the performance of the nanoparticles is crucial. In the current study, we investigated the ability of different PEGylated and non-PEGylated cationic liposomes to induce siRNA knockdown in a human ovarian cancer cell line. We resembled the expected in vivo situation by incubating the nanoparticles in undiluted ascites fluid isolated from a peritoneal carcinomatosis patient. Important parameters of the liposomal formulations that we studied were i) the release of siRNA in the ascites fluid, ii) the aggregation of the lipoplexes and iii) the effect of the biofluid on the cellular uptake of nanoparticles. All parameters were correlated with the biological performance of the liposomal formulations. Our results indicate that there is a large discrepancy between the high transfection potential of the nanoparticles seen under protein-free conditions, and their performance which remains after exposing them to a proteinrich biofluid such as human ascites fluid. Negative control siRNA (siNEG) and Luciferase siRNA (siLuc) were purchased from (Eurogentec, Searing, Belgium).
Experimental section

Materials
Preparation and characterization of the lipoplexes (LPXs)
Liposomes corresponding to 5 mM of DOTAP and 5 mM of DOPE lipids were prepared by mixing the appropriate amount of lipids in a round bottomed flask before evaporation. The average size and zeta potential of all formulations were measured by a Zetasizer Nano-ZS (Malvern, Worcestershire, UK).
Cell culture
The human ovarian cancer cell line SKOV-3 which stably expresses firefly luciferase was used Then, 300 µl LF-LPXs were added to these tubes as such or after incubation in the ascites fluid.
After 4 h of exposing the LF-LPXs to the cells, the coverslips were placed in the wells of a 24-well plate and kept in the incubator for 24 h after adding growth medium to the cells.
Subsequently the cells were lysed and the percentage of luciferase inhibition was calculated as mentioned above. It should be noted that in this upside-down transfection mode, precipitation of LF-LPXs on the cells due to gravity is avoided.
Statistical analysis (shown in Figure 1 .) was performed using GraphPad Prism 6 (GraphPad ® , USA). Statistically significant differences were calculated by using an analysis of variance (ANOVA) at a 0.05 significance level, followed by Sidak's post test. For each formulation, transfection experiment carried-out in Opti-MEM ® were compared to those in ascites.
Fluorescence Correlation Spectroscopy on LPXs
Fluorescence Correlation Spectroscopy (FCS) is a microscopy-based technique that monitors the fluorescence intensity fluctuations of (fluorescent) molecules diffusing in and out of the focal volume of a confocal microscope 7, 10 . Single color FCS measurements were performed on LPXs containing 30% Cy5 siRNA, with a +/-charge ratio of 8. Five µl of such LPXs was diluted to a final volume of 45 µl HEPES buffer or 45 µl ascites fluid (~ 90 vol% of biofluid);
The samples were analysed by FCS immediately, 1 h and 24 h after incubation in the biofluids at 37°C. During the incubation and FCS measurements, the well plate was covered with
Adhesive Plates Seals (Thermo Scientific, UK) to avoid evaporation of the sample and to minimize flow. FCS measurements were performed on the experimental set-up described before 7 .
Fluorescence single particle tracking (fSPT)
Fluorescence single particle tracking (fSPT) is a fluorescence microscopy technique which is very well suited to determine diffusion/aggregation of nanoparticles in undiluted biological fluids, as was previously shown 11 .
fSPT measurements were performed on LPXs (Cationic, 5% C16 Cer-PEG and LF-LPXs), labeled with DID or containing Alexa-Fluor 488 (AF-488) labeled siRNA. LPXs were dispersed in biofluids as follows. First, formulations were diluted 400 times in HEPES buffer. Uptake experiments were performed with LPXs as such (directly after preparation), or after incubation of the LPXs with ~70% ascites fluid for 1 h before adding them to the cells, as described above under transfection efficiency.
Results
Characterization of the liposomes and LPXs in HEPES buffer
As 
Transfection efficiency of the LPXs in protein-free and protein-rich conditions
To evaluate the ability of the LPXs to knockdown the expression of a specific gene, SKOV-3 cells stably expressing luciferase were incubated with the LPXs containing siRNA against luciferase (siLuc). To verify the knockdown specificity, formulations loaded with a scrambled sequence (siNEG) were used as well. 
Aggregation of the LPXs in undiluted human ascites fluid
In our previous study 7 , we have shown that dynamic light scattering (DLS) is not an ideal technique for quantifying the extent of aggregation of nanocarriers in (undiluted) ascites fluids, simply due to light scattering that results from the high amount of proteins in such samples. In our hands fSPT has proven to be superior over DLS to study aggregation of nanoparticles in biological fluids 7, [11] [12] [13] . Figure 3a shows the size distributions of the cationic LPXs incubated in Based on the data in Figure 4c , it is clear that very severe aggregation occurs in ascites fluids for LF-LPXs. Figure 1 demonstrates that LF-LPXs exposed to ascites fluids show the highest transfection efficiency, while the (more) colloidally stable cationic LPXs and 5% C16 CerLPXs lose their biological activity in ascites fluid (Figure 1 , white bars). One possible reason for these observations could be that the larger LF-LPXs aggregates rapidly sediment onto the cells during transfection, leading to a forced increased uptake and transfection efficiency. To test this hypothesis, the cell uptake of the lipoplexes was evaluated before and after incubation of the formulations in ascites fluid.
Influence of ascites fluid on the cellular uptake of the LPXs by SKOV-3 cells
To test the extent of LPX uptake in cells after incubation with ascites fluid, we exposed SKOV- As the uptake of nanoparticles is both charge and size dependent, aggregation of nanoparticles can potentially influence the uptake profile and subsequent transfection efficiency 14 . Therefore, we evaluated if aggregation of the nanoparticles was related to the obtained biological activity.
On the contrary to the release profile, the differences in aggregation between the formulations is much more pronounced. Aggregation is most pronounced in the case of the cationic LPXs, When nanoparticles are dispersed in extracellular fluids, proteins in these biofluids may bind at the surface of the nanoparticles, forming a so-called protein corona. It has been shown that the protein corona formed around transferrin-functionalized nanoparticles impairs their ability to bind transferrin receptors on the cell surface following incubation in fetal bovine serum and human serum [15] [16] . Also, the protein corona can alter the intracellular processing of particles, increasing the fraction that accumulates in the lysosomes 17 . Both the protein composition of the biofluid and the surface properties of the nanoparticles will determine the composition of the protein corona that is eventually formed. We have previously shown that the protein concentration in human ascites fluid is half the concentration of proteins present in human serum, while the protein composition of human ascites fluid is very similar to human serum, with albumin as main fraction (62%) 7 . We hypothesize that the poor uptake observed following incubation of cationic LPXs and PEGylated LPXs in the ascites fluid results from the surface coating of these formulations with negatively charged proteins 18 . . This points out that the detrimental effect of human ascites fluid on the internalization of nanoparticles could be a common problem for many nanoparticle formulations exposed to various biological fluids. As for nucleic acid delivery, uptake is necessary for biological activity, testing the uptake of gene delivery systems following incubation in undiluted biological fluids is extremely important and should become a routine test before performing in vivo studies. Taken together, the "protein corona field" is rapidly growing with new findings that are extremely important for translating the in vitro to the in vivo situation, but is still not getting enough attention among scientists in the RNAi delivery community.
Conclusions
Importantly, we found that good complexation and transfection properties in reduced serum ) conditions only, one runs the risk to select nanoparticles that are able to cross an empty street, hoping they will also survive the busy traffic conditions in vivo. Just like earning a driving license, however, nanoparticles should be tested in realistic in vitro conditions so that in vivo animal testing can be restricted to only those particles that passed the relevant screening conditions. Tables   Table 1. Z-Average diameter and zeta potential of the different formulations used in this study
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